Marie Blonski
Overview
Explore the profile of Marie Blonski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
809
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Margulies A, Sahki N, Rech F, Vogin G, Blonski M, Peiffert D, et al.
Radiat Oncol
. 2025 Feb;
20(1):28.
PMID: 40022217
Background: Glioblastomas all eventually relapse after initial treatment, and an option to treat these recurrences is fractionated stereotactic reirradiation (fSRT). The location of recurrences following reirradiation has not been studied...
2.
Obara T, Blonski M, Forest-Dodelin M, Rech F, Taillandier L
J Neurooncol
. 2024 Dec;
171(3):659-668.
PMID: 39680337
Purpose: Few studies have evaluated the health-related quality of life (HRQoL) of patients with diffuse low-grade glioma (LGG) during a clinical and radiological monitoring period. We report a cross sectional...
3.
Chiche D, Taillandier L, Blonski M, Planel S, Obara T, Anxionnat R, et al.
World Neurosurg
. 2024 Nov;
194:123382.
PMID: 39489335
Background: Diffuse low-grade gliomas are rare brain tumors transforming to higher grade even with surgery, chemotherapy, and radiotherapy. Their preferential infiltration of white matter tracts, beyond tumor boundaries on fluid-attenuated...
4.
Schulz N, Nichelli L, Schenone L, Ursu R, Abraham J, Le Cann M, et al.
J Neurooncol
. 2024 Jun;
169(1):51-60.
PMID: 38865013
Purpose: Immunosuppression is a well-established risk factor for primary central nervous system lymphomas (PCNSLs), which present in this context distinct radiological characteristics. Our aim was to describe the radiological evolution...
5.
Zinsz A, Ahrari S, Becker J, Mortada A, Roch V, Doriat L, et al.
J Neurooncol
. 2024 Jun;
169(2):241-245.
PMID: 38842696
Purpose: This study aimed to evaluate the prognostic performance of amino-acid PET in high-grade gliomas (HGG) patients at the time of temozolomide (TMZ) treatment discontinuation, after the Stupp protocol. Methods:...
6.
Zinsz A, Pouget C, Rech F, Taillandier L, Blonski M, Amlal S, et al.
Eur J Nucl Med Mol Imaging
. 2024 Apr;
51(9):2672-2683.
PMID: 38637354
Background: Amino acid PET is recommended for the initial diagnosis of brain lesions, but its value for identifying aggressive lesions remains to be established. The current study therefore evaluates the...
7.
Choquet S, Soussain C, Azar N, Morel V, Metz C, Ursu R, et al.
Am J Hematol
. 2024 Apr;
99(7):1240-1249.
PMID: 38586986
The prognosis of relapsed primary central nervous system lymphoma (PCNSL) remains dismal. CAR T-cells are a major contributor to systemic lymphomas, but their use in PCNSL is limited. From the...
8.
Boursier C, Zaragori T, Bros M, Bordonne M, Melki S, Taillandier L, et al.
Eur Radiol
. 2023 May;
33(10):7089-7098.
PMID: 37148355
Objectives: Tumor dosimetry with somatostatin receptor-targeted peptide receptor radionuclide therapy (SSTR-targeted PRRT) by Lu-DOTATATE may contribute to improved treatment monitoring of refractory meningioma. Accurate dosimetry requires reliable and reproducible pretherapeutic...
9.
Darcourt J, Chardin D, Bourg V, Gal J, Schiappa R, Blonski M, et al.
Eur J Nucl Med Mol Imaging
. 2023 Apr;
50(9):2727-2735.
PMID: 37086272
Background: Diagnostic value of 3,4-dihydroxy-6-[F]fluoro-L-phenylalanine ([F]FDOPA) PET in patients with suspected recurrent gliomas is recognised. We conducted a multicentre prospective study to assess its added value in the practical management...
10.
Ahmed-Khalifa T, Gillet R, Blonski M, Rech F, Fresse A, Gillet P, et al.
Fundam Clin Pharmacol
. 2023 Jan;
37(4):868-878.
PMID: 36692232
Cyproterone acetate (CPA) is known to induce meningioma, and recently, nomegestrol acetate (NMA) and chlormadinone acetate (CMA) were also involved. Progestagen-induced meningioma management starts with progestogen discontinuation and is either...